{"id":18959,"date":"2021-12-02T09:43:33","date_gmt":"2021-12-02T08:43:33","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=18959"},"modified":"2021-12-02T09:43:37","modified_gmt":"2021-12-02T08:43:37","slug":"2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/","title":{"rendered":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation"},"content":{"rendered":"\n<p>Article published on 18 November 2021 on the <a href=\"https:\/\/accesstomedicinefoundation.org\/news\/signs-of-progress-by-pharma-against-superbugs-yet-little-movement-to-address-access\" target=\"_blank\" rel=\"noreferrer noopener\">Access to medicine foundation<\/a> website<\/p>\n\n\n\n<p>The Access to Medicine (AtM) Foundation has released its 2021 antimicrobial resistance benchmark report evaluating 17 of the industry\u2019s most active players in the AMR space.\u00a0<\/p>\n\n\n\n<p>GSK maintained its lead among multinational corporations, although Pfizer leaped from sixth to a close second place after making \u201csignificant strides\u201d in stewardship, waste management, drug access, R&amp;D and data sharing. <\/p>\n\n\n\n<p>The AtM Foundation praised Pfizer as the only major multinational making its raw data public. In the generics manufacturer group, Aurobindo, Abbott and Viatris made the list as new leaders in first, second and third place, respectively.\u00a0<\/p>\n\n\n\n<p>According to the press release, \u201cgood practice is becoming more common,\u201d but industry is showing a \u201clack of momentum.\u201d Companies missed opportunities to improve access to LMICs with the highest need and \u201cremain focused on a small set of countries, people, and diseases,\u201d the report said.<\/p>\n\n\n\n<ul><li><a href=\"https:\/\/linksbridge.us13.list-manage.com\/track\/click?u=68702d1ed382bc3d7322f25ac&amp;id=4414085e84&amp;e=166208a2ca\" target=\"_blank\" rel=\"noreferrer noopener\">AtM Foundation press release<\/a><\/li><li><a href=\"https:\/\/linksbridge.us13.list-manage.com\/track\/click?u=68702d1ed382bc3d7322f25ac&amp;id=8e57707680&amp;e=166208a2ca\" target=\"_blank\" rel=\"noreferrer noopener\">AMR Benchmark 2021<\/a><\/li><li><a href=\"https:\/\/linksbridge.us13.list-manage.com\/track\/click?u=68702d1ed382bc3d7322f25ac&amp;id=0d16cbd6d7&amp;e=166208a2ca\" target=\"_blank\" rel=\"noreferrer noopener\">AMR Benchmark Report Cards<\/a><\/li><li><a href=\"https:\/\/linksbridge.us13.list-manage.com\/track\/click?u=68702d1ed382bc3d7322f25ac&amp;id=d94b3e5d75&amp;e=166208a2ca\" target=\"_blank\" rel=\"noreferrer noopener\">Reports from AtM Foundation, WHO warn about antimicrobial resistance<\/a> (January 22, 2020)<\/li><\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on 18 November 2021 on the Access to medicine foundation website The Access to Medicine (AtM) Foundation has released its 2021 antimicrobial resistance benchmark report evaluating 17 of the industry\u2019s most active players in the AMR space.\u00a0 GSK maintained its lead among multinational corporations, although Pfizer leaped from sixth to a close second [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":18977,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31,37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-02T08:43:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-02T08:43:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"796\" \/>\n\t<meta property=\"og:image:height\" content=\"596\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation\",\"datePublished\":\"2021-12-02T08:43:33+00:00\",\"dateModified\":\"2021-12-02T08:43:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\"},\"wordCount\":183,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg\",\"articleSection\":[\"Actualit\u00e9s\",\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\",\"name\":\"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg\",\"datePublished\":\"2021-12-02T08:43:33+00:00\",\"dateModified\":\"2021-12-02T08:43:37+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg\",\"width\":796,\"height\":596,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bilans, rapports et recommandations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/","og_locale":"fr_FR","og_type":"article","og_title":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2021-12-02T08:43:33+00:00","article_modified_time":"2021-12-02T08:43:37+00:00","og_image":[{"width":796,"height":596,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation","datePublished":"2021-12-02T08:43:33+00:00","dateModified":"2021-12-02T08:43:37+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/"},"wordCount":183,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg","articleSection":["Actualit\u00e9s","Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/","name":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg","datePublished":"2021-12-02T08:43:33+00:00","dateModified":"2021-12-02T08:43:37+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Lutte-lion.jpg","width":796,"height":596,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Bilans, rapports et recommandations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/"},{"@type":"ListItem","position":4,"name":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-21 06:16:26","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/18959"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=18959"}],"version-history":[{"count":11,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/18959\/revisions"}],"predecessor-version":[{"id":18985,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/18959\/revisions\/18985"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/18977"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=18959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=18959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=18959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}